Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer.
Min Chong KimSu Hwan KangJung Eun ChoiYoung Kyung BaePublished in: Journal of breast cancer (2020)
Under the 2013 guidelines, the positive and equivocal cases increased. However, the 2018 guidelines eliminated ambiguous cases by reclassifying them as HER2-negative.